{
    "organizations": [],
    "uuid": "ad081936f3e4e755acc16730b37a96a43a178301",
    "author": "",
    "url": "https://www.reuters.com/article/brief-acelrx-announces-completion-of-the/brief-acelrx-announces-completion-of-the-human-factors-study-for-dsuvia-and-confirms-plans-to-resubmit-nda-idUSFWN1RT0H8",
    "ord_in_thread": 0,
    "title": "BRIEF-Acelrx Announces Completion Of The Human Factors Study For Dsuvia And Confirms Plans To Resubmit NDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 06 AM / Updated 10 minutes ago BRIEF-Acelrx Announces Completion Of The Human Factors Study For Dsuvia And Confirms Plans To Resubmit NDA Reuters Staff 1 Min Read \nApril 16 (Reuters) - AcelRx Pharmaceuticals Inc: \n* ACELRX ANNOUNCES COMPLETION OF THE HUMAN FACTORS STUDY FOR DSUVIA AND CONFIRMS PLANS TO RESUBMIT NDA IN Q2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-16T14:04:00.000+03:00",
    "crawled": "2018-04-16T14:21:23.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "announces",
        "completion",
        "human",
        "factor",
        "study",
        "dsuvia",
        "confirms",
        "plan",
        "resubmit",
        "nda",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "acelrx",
        "pharmaceutical",
        "inc",
        "acelrx",
        "announces",
        "completion",
        "human",
        "factor",
        "study",
        "dsuvia",
        "confirms",
        "plan",
        "resubmit",
        "nda",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}